Results 61 to 70 of about 2,960,910 (293)

circulating tumor DNA in the immediate post-operative setting

Annals of Surgical Oncology, 2023
Abstract Background Circulating tumor DNA (ctDNA) has emerged as an accurate real-time biomarker of disease status across most solid tumor types. Most studies evaluating the utility of ctDNA have focused on time points weeks to months after surgery, which for many cancer types, is significantly later
Vasileios Efthymiou, Natalia Queenan, Markus Haas, Saskia Naegele, Deborah Goss, Daniel L. Faden   +5 more
openaire   +3 more sources

Liver organoids: modelling complexity in homeostasis and disease

FEBS Letters, EarlyView.
Studying liver in vitro has been challenging because simple 2D cell cultures fail to capture liver's cellular and architectural complexity. To bridge this gap, scientists increasingly use organoids, 3D liver models which better mimic liver composition and function. This review examines recent advances in liver organoid complexity and realism, discusses
Anna M. Dowbaj, Meritxell Huch
wiley   +1 more source

Liquid biopsy in gallbladder carcinoma: Current evidence and future prospective

The Journal of Liquid Biopsy
Although there have been significant advances in the early detection and treatment of gallbladder cancer (GBC), it is still considered a leading cause of morbidity and mortality. Molecular profiling of tumors is generally performed using samples obtained
Sridhar Mishra, Swati Kumari, Nuzhat Husain   +2 more
doaj   +1 more source

Evaluation of exome sequencing to estimate tumor burden in plasma. [PDF]

PLoS ONE, 2014
Accurate estimation of systemic tumor load from the blood of cancer patients has enormous potential. One avenue is to measure the presence of cell-free circulating tumor DNA in plasma.
Daniel Klevebring, Mårten Neiman, Simon Sundling, Louise Eriksson, Eva Darai Ramqvist, Fuat Celebioglu, Kamila Czene, Per Hall, Lars Egevad, Henrik Grönberg, Johan Lindberg   +10 more
doaj   +1 more source

Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy [PDF]

Cancer Discovery, 2016
Abstract “Liquid biopsy” focusing on the analysis of circulating tumor cells (CTC) and circulating cell-free tumor DNA (ctDNA) in the blood of patients with cancer has received enormous attention because of its obvious clinical implications for personalized medicine. Analyses of CTCs and ctDNA have paved new diagnostic avenues and are,
C. Alix-Panabieres, K. Pantel
openaire   +2 more sources

Genotyping tumor DNA for precision oncology

, 2022
The genomic revolution marked the beginning of the 21st century in biology and medicine. Completion of the Human Genome Project in 2003 has brought a flood of technological innovations that enabled decoding the entire genetic information in health and ...
Silveira, Catarina
core  

Nucleosomes in serum as a marker for cell death [PDF]

, 2001
The concentration of nucleosomes is elevated in blood of patients with diseases which are associated with enhanced cell death. In order to detect these circulating nucleosomes, we used the Cell Death Detection-ELISA(Plus) (CDDE) from Roche Diagnostics ...
Holdenrieder, Stefan, Dietrich Seidel, Seidel, Dietrich, Michael Untch, Fertig, Georg, Stieber, Petra, Fürst, Heinrich, Georg Fertig, Nikolaus Schmeller, Heinz Bodenmüller, Stefan Holdenrieder, Schmeller, Nikolaus, Heinrich Fürst, Bodenmüller, Heinz, Untch, Michael, Petra Stieber   +15 more
core   +1 more source

Epigenetic reprogramming of lineage switching in cancer

FEBS Letters, EarlyView.
Cancer cells rarely commit to a single identity. Epigenetic mechanisms and tumor microenvironment cues push epithelial cells toward flexible, hybrid states that can shift into mesenchymal, neuroendocrine, or stem‐like fates, driving metastasis, drug resistance, and tumor heterogeneity. Targeting the epigenetic regulators behind these transitions, using
Ezgi Boyvatlı, Burcu Akman, Ezgi Bağırsakçı, Nese Atabey, Serap Erkek‐Ozhan   +4 more
wiley   +1 more source

Ligand‐dependent transcriptional heterogeneity in cell cycle gene expression delays G1/S entry

FEBS Letters, EarlyView.
EGF and HRG induce distinct G1/S progression programs in ErbB2‐amplified BT474 breast cancer cells. Despite activating the potent ErbB2–ErbB3 heterodimer, HRG does not accelerate cell‐cycle entry. Instead, EGF promotes earlier restriction‐point passage via ERK–FOS signaling, whereas HRG activates the AKT–MYC axis, driving transcriptional heterogeneity ...
Ririn Rahmala Febri, Ayaka Nagasato‐Ichikawa, Keita Iida, Shuhei Kimura, Akira Imamoto, Mariko Okada   +5 more
wiley   +1 more source

Circulating free tumor DNA and colorectal cancer

, 2010
International audienceCancer is characterized by multiple somatic genetic and epigenetic alterations that could be useful as molecular markers for detecting tumor DNA in different bodily fluids.
Lecomte, Thierry, Laurent-Puig, Pierre, Ceze, Nicolas, Dorval, Etienne   +3 more
core   +2 more sources